Brief: Ipsen’S Iqirvo® Receives U.S. FDA Accelerated Approval As A First-In-Class Ppar Treatment For Primary Biliary Cholangitis
10/06/2024 22:30
Ipsen SA IPN.PA :
* IPSEN’S IQIRVO® RECEIVES U.S. FDA ACCELERATED APPROVAL AS
A
FIRST-IN-CLASS PPAR TREATMENT FOR PRIMARY BILIARY CHOLANGITIS
* IPSEN SA - IQIRVO MAY BE PRESCRIBED IMMEDIATELY IN U.S.
FOR
ELIGIBLE PATIENTS.
Source text for Eikon: ID:nGNX4PqCPH
Further company coverage: IPN.PA
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients